Publications by authors named "Seth A Wander"

Claim this Profile
C
Current landscape of sequencing ADCs in metastatic breast cancer.
Shannon McLaughlin, Lis V Ravani, Beverly Moy, Arielle J Medford, Steven J Isakoff, Seth A Wander

Ther Adv Med Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diffuse peritoneal inclusion cysts masquerading as disseminated gynecologic malignancy in post-menopausal females: Two cases and a review of the literature.
Hadley W Reid, Seth A Wander, Carlos Parra-Herran, Victoria Wang, Valentina Zanfagnin

Int J Gynaecol Obstet· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine.
Arielle J Medford, Seth A Wander

Nat Rev Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer.
Maxwell R Lloyd, Caroline M Weipert, Azka Ali, Sheila R Solomon, Jayati Saha, Seth A Wander

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer.
Hope S Rugo, Virginia Kaklamani, Heather McArthur, Seth A Wander, William Gradishar

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
Robert Wesolowski, Hope S Rugo, Jennifer M Specht, Hyo S Han, Peter Kabos, Seth A Wander

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Comparative efficacy of first- versus second-line CDK4/6 Inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer.
Victoria Lis Ravani, Zahra Bagheri, Adam M Brufsky, Isabella Michelon, Ruth O'Regan, Seth A Wander

Breast Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging real-world evidence to personalize adjuvant therapy in HR+/HER2- early breast cancer.
Yael Bar, Steven J Isakoff, Seth A Wander

JNCI Cancer Spectr· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer.
Maxwell R Lloyd, Rosario Chica-Parrado, Caroline M Weipert, Todd C Knepper, Emily L Podany, Seth A Wander

EBioMedicine· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 40-year-old woman with early-stage triple-negative breast cancer and a retinal lesion.
Shivahamy Maheswaran, Arielle J Medford, Tomasz P Stryjewski, Janice N Thai, Seth A Wander

Breast Cancer Res Treat· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer.
Lis Victoria Ravani, Zahra Bagheri, Adam M Brufsky, Isabella Michelon, Ruth O'Regan, Seth A Wander

Breast Cancer Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
POLARIS and Emerging Translational Efforts to Interrogate the Genomic Landscape of CDK4/6 Inhibitor Resistance.
Elena Michaels, Seth A Wander

JCO Precis Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor-Positive Advanced Breast Cancer.
Lis Victoria Ravani, Pedro Calomeni, Maysa Vilbert, Thiago Madeira, Ming Wang, Seth A Wander

JCO Oncol Pract· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor-Positive Metastatic Breast Cancer.
Jimmitti Teysir, Maxwell R Lloyd, Samer Alkassis, Rena D Callahan, Ricki Fairley, Seth A Wander

Am Soc Clin Oncol Educ Book· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.
Rachel O Abelman, Bogang Wu, Haley Barnes, Arielle Medford, Bryanna Norden, Seth A Wander

Clin Cancer Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, -mutated, metastatic breast cancer.
Matthew P Goetz, Seth A Wander, Thomas Bachelot, Alexandre de Nonneville, Einav Nili Gal-Yam

Future Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.
Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, Stephanie L Graff, Kyong Hwa Park, Seth A Wander

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies.
Yael Bar, Geoffrey Fell, Aylin Dedeoglu, Natalie Moffett, Neelima Vidula, Seth A Wander

NPJ Breast Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell cycle dysregulation in cancer.
Antonino Glaviano, Samarendra K Singh, E Hui Clarissa Lee, Elena Okina, Hiu Yan Lam, Seth A Wander

Pharmacol Rev· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).
Laura M Spring, Lauren Scarpetti, Arielle J Medford, Andrzej Niemierko, Amy Comander, Seth A Wander

NPJ Breast Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer.
Erika P Hamilton, Cynthia Ma, Michelino De Laurentiis, Hiroji Iwata, Sara A Hurvitz, Seth A Wander

Future Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer.
Maxwell R Lloyd, Komal Jhaveri, Kevin Kalinsky, Aditya Bardia, Seth A Wander

Nat Rev Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment.
Antonino Glaviano, Seth A Wander, Richard D Baird, Kenneth C-H Yap, Hiu Yan Lam

Drug Resist Updat· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case 26-2024: A 59-Year-Old Woman with Aphasia, Anemia, and a Breast Mass.
Seth A Wander, Janice N Thai, Lori J Wirth, Daniel E Soto, Rebecca M Kwait

N Engl J Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDK4/6 Inhibitor Efficacy in -Mutant Metastatic Breast Cancer.
Maxwell R Lloyd, Jamie O Brett, Ariel Carmeli, Caroline M Weipert, Nicole Zhang, Seth A Wander

NEJM Evid· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis